Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Naturally Splendid Enterprises Ltd V.NSP.H

Alternate Symbol(s):  NSPDF

Naturally Splendid Enterprises Ltd. is a Canada-based company, which develops and distributes healthy lifestyle foods and products. The Company owns Prosnack Natural Foods Inc. (Prosnack Natural Foods), a food manufacturing facility. Prosnack Natural Foods focusses on nutritional bars, Chii Naturally Pure Hemp, which is a retail line of hemp food products, while Pawsitive FX is a line of all natural balms for dogs. The Company has also developed technologies for the extraction of healthy omega three and six oils, as well as a protein concentrate from hemp. It focuses on manufacturing and distributing an extensive line of plant-based, meat-alternative entrees. It offers functional foods under brands, such as Natera Sport, Natera Hemp Foods, CHII and Elevate Me.


TSXV:NSP.H - Post by User

Post by dontknowmuchon Jun 01, 2020 9:02am
194 Views
Post# 31095419

Inventory Produced for Target Drug, Cavaltinib(TM)

Inventory Produced for Target Drug, Cavaltinib(TM)
June 1, 2020 - 8:35 AM EDT
Print Email Article Font Down Font Up Charts
NSP:CA 0.065   -0.005
Today 5d 1m 3m 1y 5y 10y
NSPDF 0.0455   -0.0026
Today 5d 1m 3m 1y 5y 10y
Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial

(via TheNewswire)



   

 

Vancouver, British Columbia - TheNewswire - June 1, 2020 - Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to provide the following progress update for a Phase 2 clinical trial treatment for COVID 19.

The Company is now awaiting notification by Health Canada to proceed to the Phase 2 clinical trial stage, by way of a No Objection Letter (NOL). Health Canada reviews all Clinical Trial Applications and notifies the sponsor within 30 calendar days if the application is found to be deficient. If the application is deemed acceptable, a No Objection Letter (NOL) will be issued within the 30-day review period.

In preparation, the Company has produced the required quantity of Cavaltinib(TM), the target drug for a Phase 2 clinical trial, and holds it in inventory. In addition, agreements with Pharma grade manufacturing facilities with a history of producing products based on Biologic patented technologies, have been put in place allowing for scaling up production capacities in proactive anticipation of much greater volumes of Cavaltinib(TM) being required for Phase 3 clinical studies and/or distribution to patents. Two (2) facilities have been identified in Canada and two (2) facilities in the United States.

This combined manufacturing capacity would be sufficient for commercial production to serve international markets and provide for manufacturing contingency plans should it be required

As set out in Naturally Splendid's news release dated May 19, 2020, Naturally Splendid entered into a letter of intent with Biologic Pharmamedical (Biologic) to form of a joint venture for the purpose of developing and pursuing Phase 2 clinical studies, utilizing one of Biologic's patented technologies as a candidate for a potential COVID-19 treatment. The proposed joint venture entity will be granted certain rights from Biologic's patents as it relates to applications for treating COVID-19 infections. The categories to be licensed will include, but are not limited to COVID-19 applications, as well as additional respiratory indications that may arise out of the Phase 2 clinical trial.
 

About CavaltinibTM

CavaltinibTM displays novel pharmacology discovered by Biologic and shown today to be a potential fit as a drug candidate for COVID-19 patient treatment. This candidate drug has been run through Biologic's research program that was designed to study key drug targets involved in the regulation of immune system and inflammatory activity. The research has already shown Cavaltinib(TM) irrefutably inhibits IL-6 and several other cytokines central to the 'cytokine storm' phenomenon. The Company believes CavaltinibTM will show the same positive results in mitigating the 'cytokine storm' with COVID-19 patients.

Biologic Pharmamedical's research methodology for probing key drug targets with this novel drug is based on rigorous clinical study that utilizes accepted allopathic research protocols, thus affirming for medical practitioners the efficacy of Biologic's subject drugs - both nutraceutical or pharmaceutical - with methods and results that are familiar to mainstream medical practitioners.

We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time.

The scientific content of this news release has been reviewed and approved by Biologic.


Bullboard Posts